Simmons, Daniel J.
Valerio, Stephen J.
Thomas, Darren S.
Healey, Marcus J.
Jiang, Zhuoxin
Levingston Mac Leod, Jesica M.
Lin, Yian
Sah, Janvi
Funding for this research was provided by:
AstraZeneca
Article History
Received: 25 October 2023
Accepted: 15 January 2024
First Online: 5 March 2024
Declarations
:
: Daniel J. Simmons: Employee and shareholder of AstraZeneca. Stephen J. Valerio: Employee and shareholder of AstraZeneca. Darren S. Thomas: Employee and shareholder of AstraZeneca. Marcus J. Healey: Former full-time employee of AstraZeneca at time of study. Current full-time employee of PharmaPRMAx, LLC. Zhuoxin Jiang: Former full-time employee of AstraZeneca at time of study. Current full-time employee of Daiichi Sankyo, Inc. Jesica M. Levingston Mac Leod: Employee of AstraZeneca. Yian Lin: Former full-time employee and shareholder of AstraZeneca at time of study. Current full-time employee of Novartis Pharmaceuticals Corporation. Janvi Sah: Employee and shareholder of AstraZeneca.
: This was a retrospective study using anonymous data; therefore, ethics committee approval was not required. However, the data were certified as de-identified by an independent statistical expert following the statistical de-identification rules of the Health Insurance Portability and Accountability Act (HIPAA) and managed according to customer data use agreements. Study authors received permission to use the Optum<sup>®</sup> Clinformatics<sup>®</sup> Data Mart claims database from Optum<sup>®</sup>.